Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma once again looks to Amgen

William Go and Jeff Aycock fourth and fifth senior figures to join from Amgen this year

Kite Pharma has appointed two former Amgen directors to senior positions in its research team.

Dr William Go joins as senior director, clinical development, and Jeff Aycock joins as senior director, clinical operations. 

Dr Go was most recently US medical lead for Amgen's cancer treatments Vectibix (panitumumab) and medical director in the company's global development business. Aycock, meanwhile, was most recently director, oncology study management and US regional lead at Amgen, overseeing five oncology programmes.

The two will now add their expertise in cancer to Kite as it plans to advance its immunotherapy plans in oncology.

They are the fourth and fifth senior figures to make their way from Amgen to Kite this year, following the appointments of VP, clinical development, Dr Jeffrey Wiezorek in May and of chief medical officer Dr David Chang earlier this month to replace Dr Keith Nolop who spent just one year in the role.

Outside R&D, Kite also added Dr Rizwana Sproule from Amgen as head VP, regulatory affairs in January.

24th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics